Gene therapy trial hopes to slow duchenne muscular dystrophy in young boys
NCT ID NCT07058662
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-stage study tests a gene therapy called BBM-D101 in 9 boys aged 4 to 8 with Duchenne muscular dystrophy (DMD). The goal is to see if it is safe and can help produce a missing protein in muscles. Researchers will monitor side effects and measure changes in muscle health over time.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for DMD are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Peking Union Medical College Hospital
RECRUITINGBeijing, Beijing Municipality, 100730, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a targeted infusion slow muscle decline in duchenne? a new trial aims to find out.
- New drug could help boys with duchenne walk and move longer
- Could a common ED drug and cycling help kids with duchenne?
- Hope for duchenne: new drug targets rare gene mutation in phase 3 trial
- Swiss launch major registry to track rare muscle diseases
- New pill for duchenne MD enters Mid-Stage trial in young boys